Peter joined the Group in 2015 as Head of Life Sciences & Biosciences, with over 20 years’ experience in this sector, and became Chief Operating Officer in 2018. He is now Managing Director Mercia Ventures, responsible for the Northern VCTs, retaining a specialism in Life Sciences, responsible for a number of portfolio investments including Locate Bio, Newcells, Axis Spine Technologies, and  Biological Preparations, and in July 2020 he oversaw the successful exit of The Native Antigen Company.

Previous experience

Peter has been involved with a number of turnarounds and exits within the sector, including the acquisition of Surgicraft’s loss-making business where, as Managing Director, sales quadrupled within three years and the business was subsequently sold to a private equity-backed business and Diagnostic World, a fast-growing diagnostic provider to the NHS, which later re-branded as C7 Health and successfully exited in 2022.